{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valine",
    "query": {
      "intervention": "Valine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 130,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T10:00:01.765Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04467931",
      "title": "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypertension",
        "COVID"
      ],
      "interventions": [
        {
          "name": "ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "Non-ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "ACEI",
          "type": "DRUG"
        },
        {
          "name": "ARB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22213,
      "start_date": "2020-01-19",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467931"
    },
    {
      "nct_id": "NCT04969536",
      "title": "Metabolomic Impacts of Branched-chain Amino Acid Supplementation During Endurance Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Branched Chain Amino Acids",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Montana State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-10-01",
      "completion_date": "2021-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969536"
    },
    {
      "nct_id": "NCT00809926",
      "title": "8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stage 2 Hypertension"
      ],
      "interventions": [
        {
          "name": "Valsartan/aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 451,
      "start_date": "2009-01",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2011-05-02",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809926"
    },
    {
      "nct_id": "NCT00240448",
      "title": "A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "telmisartan 80 mg/hydrochlorothiazide 25 mg",
          "type": "DRUG"
        },
        {
          "name": "valsartan 160 mg/hydrochlorothiazide 25 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1109,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 100,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sctoosdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240448"
    },
    {
      "nct_id": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Metastatic Breast Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Refractory Breast Carcinoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory Mycosis Fungoides",
        "Refractory Nodal Marginal Zone Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Belinostat",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-03-27",
      "completion_date": "2022-10-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-26",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432741"
    },
    {
      "nct_id": "NCT04743063",
      "title": "Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure, Systolic",
        "Frailty"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin II Receptor Blockers",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 40000,
      "start_date": "2021-01-14",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743063"
    },
    {
      "nct_id": "NCT00171041",
      "title": "A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 265,
      "start_date": "2002-12",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2016-11-18",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "E.Hanover, New Jersey",
      "locations": [
        {
          "city": "E.Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00171041"
    },
    {
      "nct_id": "NCT00273299",
      "title": "Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "valsartan plus hydrochlorothiazide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 607,
      "start_date": "2005-11",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2011-11-08",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273299"
    },
    {
      "nct_id": "NCT01638533",
      "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lymphoma",
        "Metastatic Malignant Solid Neoplasm",
        "Neuroendocrine Neoplasm",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage III Lung Cancer AJCC v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Lung Cancer AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Prostate Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2012-08-03",
      "completion_date": "2020-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01638533"
    },
    {
      "nct_id": "NCT00277472",
      "title": "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Valsartan/Hydrochlorothiazide",
          "type": "DRUG"
        },
        {
          "name": "HCTZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2005-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-06-07",
      "last_synced_at": "2026-09-05T10:00:01.765Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277472"
    }
  ]
}